Better Therapeutics Balance Sheet Health
Financial Health criteria checks 2/6
Better Therapeutics has a total shareholder equity of $-9.9M and total debt of $14.3M, which brings its debt-to-equity ratio to -144%. Its total assets and total liabilities are $10.7M and $20.7M respectively.
Key information
-144.0%
Debt to equity ratio
US$14.31m
Debt
Interest coverage ratio | n/a |
Cash | US$6.60m |
Equity | -US$9.94m |
Total liabilities | US$20.66m |
Total assets | US$10.72m |
Recent financial health updates
Recent updates
Better Therapeutics files for FDA approval of new type of digital therapy for diabetes
Sep 22Better Therapeutics GAAP EPS of -$0.42 in-line
Aug 11Better Therapeutics: App-Based Therapeutics, Doesn't Look Novel
May 12Better Therapeutics: Pioneering Prescription Digital Therapeutics Platform For Cardiometabolic Diseases
Nov 30Financial Position Analysis
Short Term Liabilities: BTTX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BTTX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BTTX has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BTTX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BTTX has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: BTTX is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.